Literature DB >> 23648300

[Low dose volume histogram analysis of the lungs in prediction of acute radiation pneumonitis in patients with esophageal cancer treated with three-dimensional conformal radiotherapy].

Wen-bin Shen1, Shu-chai Zhu, Hong-mei Gao, You-mei Li, Zhi-kun Liu, Juan Li, Jing-wei Su, Jun Wan.   

Abstract

OBJECTIVE: To investigate the predictive value of low dose volume of the lung on acute radiation pneumonitis (RP) in patients with esophageal cancer treated with three-dimensional conformal radiotherapy (3D-CRT) only, and to analyze the relation of comprehensive parameters of the dose-volume V5, V20 and mean lung dose (MLD) with acute RP.
METHODS: Two hundred and twenty-two patients with esophageal cancer treated by 3D-CRT have been followed up. The V5-V30 and MLD were calculated from the dose-volume histogram system. The clinical factors and treatment parameters were collected and analyzed. The acute RP was evaluated according to the RTOG toxicity criteria.
RESULTS: The acute RP of grade 1, 2, 3 and 4 were observed in 68 (30.6%), 40 (18.0%), 8 (3.6%) and 1 (0.5%) cases, respectively. The univariate analysis of measurement data:The primary tumor length, radiation fields, MLD and lung V5-V30 had a significant relationship with the acute RP. The magnitude of the number of radiation fields, the volume of GTV, MLD and Lung V5-V30 had a significant difference in whether the ≥ grade 1 and ≥ grade 2 acute RP developed or not. Binary logistic regression analysis showed that MLD, Lung V5, V20 and V25 were independent risk factors of ≥ grade 1 acute RP, and the radiation fields, MLD and Lung V5 were independent risk factors of ≥ grade 2 acute RP. The ≥ grade 1 and ≥ grade 2 acute RP were significantly decreased when MLD less than 14 Gy, V5 and V20 were less than 60% and 28%,respectively. When the V20 ≤ 28%, the acute RP was significantly decreased in V5 ≤ 60% group. When the MLD was ≤ 14 Gy, the ≥ 1 grade acute RP was significantly decreased in the V5 ≤ 60% group. When the MLD was >14 Gy, the ≥ grade 2 acute RP was significantly decreased in the V5 ≤ 60% group.
CONCLUSIONS: The low dose volume of the lung is effective in predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-CRT only. The comprehensive parameters combined with V5, V20 and MLD may increase the effect in predicting radiation pneumonitis.

Entities:  

Mesh:

Year:  2013        PMID: 23648300     DOI: 10.3760/cma.j.issn.0253-3766.2013.01.010

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  4 in total

1.  Predictive factors for acute radiation pneumonitis in postoperative intensity modulated radiation therapy and volumetric modulated arc therapy of esophageal cancer.

Authors:  Yaqin Zhao; Lu Chen; Shu Zhang; Qiang Wu; Xiaoqin Jiang; Hong Zhu; Jin Wang; Zhiping Li; Yong Xu; Ying Jie Zhang; Sen Bai; Feng Xu
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

2.  Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer.

Authors:  Mark E Bernard; Scott M Glaser; Beant S Gill; Sushil Beriwal; Dwight E Heron; James D Luketich; David M Friedland; Mark A Socinski; Joel S Greenberger
Journal:  Front Oncol       Date:  2017-01-23       Impact factor: 6.244

3.  Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation.

Authors:  Jing Li; Hongqi Li; Yingjie Wang; Junyang Liu; Xuan Wang; Haifeng Pang; Dongshu Chang; Yupeng Di; Gang Ren; Ping Li; Yong Wang; Chen Liu; Xiao Chen; Xiaoli Kang; Tingyi Xia
Journal:  Biomed Res Int       Date:  2020-06-30       Impact factor: 3.411

4.  Bio-physic constraint model using spatial registration of delta 18F-fluorodeoxyglucose positron emission tomography/computed tomography images for predicting radiation pneumonitis in esophageal squamous cell carcinoma patients receiving neoadjuvant chemoradiation.

Authors:  Tien-Chi Hou; Kun-Yao Dai; Ming-Che Wu; Kai-Lung Hua; Hung-Chi Tai; Wen-Chien Huang; Yu-Jen Chen
Journal:  Onco Targets Ther       Date:  2019-08-13       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.